We employed NEP25 mouse model for exploring the effects of therapeutic interventions of an AXL inhibitor because the model can follow the clinical course of glomerular nephritis followed by tubulointerstitial fibrosis within three weeks [26]. This evidence concerns the gene AXL and glomerulonephritis.